Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies (NASDAQ: NMTC) has received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System, designed to treat facial pain through radiofrequency lesioning. The system features a pioneering multi-contact RF probe that enables both precise localization and targeted ablation of pain-conducting nerve tissue.

The technology targets trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people annually in the United States. NeuroOne plans a limited commercial launch in Q4 2025, with potential revenue generation beginning in late 2025. The company aims to expand the OneRF® technology platform to address additional pain management applications, including lower back pain treatment.

NeuroOne Medical Technologies (NASDAQ: NMTC) reported strong Q3 FY2025 financial results, with product revenue surging 105% year-over-year to $1.7 million and gross margin expanding to 53.9%. The company successfully completed an oversubscribed $8.2 million capital raise, securing funding through FY2026.

Key operational highlights include the first OneRF® Ablation System patient achieving one-year seizure freedom, FDA submission for the OneRF® Trigeminal Nerve Ablation System, and receipt of the first order for their sEEG-based drug delivery system from a major biopharmaceutical company. The company strengthened its IP portfolio with 17 patents and received USPTO allowance for a key manufacturing patent.

NeuroOne maintains its FY2025 product revenue guidance of $8.0-$10.0 million, representing 132-190% growth, and increased gross margin expectations to 50-53%.

NeuroOne Medical Technologies (NASDAQ: NMTC), a medical technology company specializing in neurological disorder treatments, has scheduled its fiscal third quarter 2025 earnings release and conference call. The company will announce financial results for the quarter ended June 30, 2025, before market open on August 14, 2025.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern Time to discuss quarterly results and provide a corporate update. The call will include a Q&A session for telephone participants, with replay access available until August 28, 2025.

NeuroOne Medical Technologies (Nasdaq: NMTC) has received a notice of allowance from the USPTO for a key patent titled "Methods for Making Probe Devices and Related Devices." The patent application (17/392,773) covers novel methods for manufacturing neural probe devices, including specific processes for probe component arrangement and electrode contact material deposition.

The company's intellectual property portfolio now encompasses 17 issued and pending patents across the U.S. and internationally, covering various thin-film electrode technologies. The patent is expected to be formally issued in the coming months, strengthening NeuroOne's position in neural and spinal cord electrode technology.

NeuroOne Medical Technologies Corporation announced a significant milestone as Clara, one of their early patients treated with the OneRF® Ablation System, has remained seizure-free for over a year. Prior to treatment in June 2024, Clara experienced up to 10 seizures daily. The OneRF® Ablation System, which is FDA 510(k)-cleared, is unique as the first device allowing both diagnostic and therapeutic applications using the same sEEG electrode, with bedside ablation capability. The technology has shown promising results in seizure reduction or elimination for most treated patients. NeuroOne is now expanding the technology's applications, having filed a 510(k) submission for a Trigeminal Nerve Ablation System to treat facial pain in April 2025. Clara's successful treatment has enabled her to pursue college full-time and enjoy daily activities previously impacted by seizures.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Emily Johns as General Counsel and Corporate Secretary. Johns, previously a partner at Honigman LLP, brings extensive experience in securities and corporate governance, having represented NeuroOne since 2017. CEO Dave Rosa highlighted that Johns' appointment would strengthen the management team while reducing legal costs. As part of her compensation, Johns received options to purchase 500,000 shares at $0.611 per share. Additionally, the company granted its new senior director of quality assurance and regulatory affairs options for 75,000 shares under the same terms, with 25% vesting after one year and the remainder in quarterly installments.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder surgical care solutions, has announced its participation in the upcoming MedInvest MedTech, AI and Digital Health Conference. The event will take place on June 3-4, 2025, at the O'Melveny Conference Center in San Francisco, CA.

Dave Rosa, President and CEO of NeuroOne, will be conducting investor meetings during this two-day conference, which will feature panel discussions, keynote talks, and corporate presentations focusing on medical devices, imaging technologies, diagnostics, AI/data analytics, and digital health. The MedInvest Conference is recognized as a leading conference series in Healthcare and Life Sciences, hosting semiannual events in Biotech, Pharma, MedTech, AI, and Digital Health sectors.

NeuroOne Medical Technologies (NASDAQ: NMTC) reported strong Q2 FY2025 financial results, with significant gross margin improvement to 55.6% from 28.3% YoY. Product revenue remained stable at $1.4M for Q2, while H1 FY2025 product revenue grew 98% to $4.7M. The company successfully filed an FDA submission for its OneRF® Trigeminal Nerve Ablation System ahead of schedule and completed an oversubscribed $8.2M capital raise in April 2025.

The company reaffirmed its FY2025 product revenue guidance of $8.0-10.0M, representing 132-190% growth YoY. NeuroOne strengthened its management team with key appointments and remains debt-free, with funding secured through FY2026. The first patient treated with OneRF Ablation System will reach one year of seizure freedom in June 2025, marking a significant milestone for the company's technology.

NeuroOne Medical Technologies (NASDAQ: NMTC) has appointed Dr. Parag G. Patil as Chief Medical Advisor (CMA), upgrading his role from the company's Scientific Advisory Board where he has served since 2018. Dr. Patil, a neurosurgeon-engineer with 20 years of experience, is currently an Associate Professor at the University of Michigan in multiple departments and serves as Associate Chair for Clinical and Translational Research.

Dr. Patil's expertise spans electrophysiology, imaging, and mathematical modeling, with a focus on developing improved therapies for paralysis, pain, and movement disorders using neural-interface devices. In his new role, he will assist with NeuroOne's clinical strategy, product development, physician education, and professional society partnerships while maintaining his faculty position.